FDA Approved: TRIUMEQ PD — Supplemental Application (ViiV Healthcare Company)

View source ↗

Summary

FDA approved a supplemental application for TRIUMEQ PD, a fixed-dose combination of abacavir sulfate, dolutegravir sodium, and lamivudine from ViiV Healthcare.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TRIUMEQ PD (ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE)

Snippet

SUPPL AP for TRIUMEQ PD (ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE)